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ABSTRACT 
Objective: The aim of this study is to estimate direct medical costs attributable to obesity in 
Kazakhstan from the governmental perspective for 2008, 2020 and 2030. 
Method: Cost-of-illness prevalence-based approach was used to estimate the medical direct 
costs including hospital care, drugs, physician and nursing care covered by the government. 
There are three types of data required for this study including the actual and predicted 
estimates of prevalence of the obesity in Kazakhstan for 2008, 2020 and 2030, relative risks 
for IHD, stroke and T2D and costs on specific disease treatment. All the required information 
was taken from the secondary data. Thus, the main formula includes multiplying Population 
Attributable Fraction by the costs for diseases’ treatment.   
Results:  Medical direct costs estimation showed the overall increasing trend through 2008, 
2020 and 2030 years for every disease. By 2030 the costs for IHD will reach 7,452,576.96 
USD, for stroke - 4,275,743.073 USD, and for T2D - 80,739,123.58 US. So, comparing to the 
costs estimates for 2008 direct medical costs covered by government in Kazakhstan are going 
to increase twice for IHD and stroke and by ⅓ for T2D complications by 2030.   
Discussion and Conclusion: Costs associated with IHD, stroke and T2D complications 
attributable to obesity in Kazakhstan by 2020 will reach 81,608,691 KZT accounting for 
11.3% from the money dedicated for 2019 of the Governmental Program for Healthcare 
Development “Densaulyk” for 2016-2019. Taking into account that no adjustments were used 
for the future currency changes, medical services and drug costs the future direct medical 
costs might be significantly higher than it was estimated in the study.  It should be mentioned 
that significant amount of money might be saved in the future if required actions are taken by 
the government.     
Key words: Obesity; overweight; Kazakhstan; cost; cost of illness 
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1. INTRODUCTION 
Recently Asian countries have experienced fast economic development. It has been resulted 
in turning from the agriculture to the manufacturing and service that, in turn, led to physical 
inactivity and available cheap food products. Although it gave opportunity to decrease 
wasting and stunting, it followed by overeating and needless weight increase. The 
phenomenon of changed eating pattern resulted from economic growth has been called 
“global nutritional transition” (Helbe & Francisco, 2017). 
As a result, global nutritional transition had a major effect on the public health including 
both, communicable and non-communicable diseases. Since the vaccines development and 
sanitation has been progressing over the years there has been significant drop in 
communicable disease spread. However, the trend of non-communicable diseases attributable 
to excess body weight is increasing steadily requiring immediate healthcare solutions (Helbe 
& Francisco, 2017).  
There is a substantial amount of evidence showing causal association between overweight 
and obesity and co-morbidities causing further extended costs for the treatment. According to 
meta-analysis conducted by Guh et al. (2009) there are 18 co-morbidities associated with 
overweight and obesity which are type II diabetes, different types of cancer (breast, 
colorectal, endometrial, esophageal, kidney, ovarian, pancreatic, and prostate), CVDs 
(including hypertension, coronary artery disease, congestive heart failure, pulmonary 
embolism, stroke) and other such as asthma, gallbladder disease, osteoarthritis, chronic back 
pain.  
For this purpose, a number of studies has been conducted on the obesity cost estimates among 
developed countries, whereas there are a few for Asian regions and developing countries. For 
example, evaluated costs for overweight and obese population in the US are around 2,741 
USD per year. Moreover, taking into account decreased productivity and absenteeism at the 
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workplaces business costs spending increases to 66 billion USD per year (Helbe & Francisco, 
2017).  
Economic costs of obesity have not been evaluated enough for many Asian regions including 
Kazakhstan in spite of extensive knowledge regarding prevalence, determinants and 
consequences.  
 
1.1 DEFINITION OF OBESITY 
Overweight and obesity have been defined as body condition with extra body fat and, 
consequently, body weight that might negatively affect individual’s health. Major sources 
determine overweight and obesity using a body mass index (BMI) equal to or more than 25 
and 30, respectively. BMI is calculated by dividing the weight in kilograms by the square of 
the height in meters (kg/m2) (WHO, 2018). It should be noticed, however, there are 
alternative measures for the overweight and obesity including waist circumference, waist to 
height ratio, waist to hip ratio and body fat measure. One of the reasons for replacing BMI 
with other measures is that some ethnicities have different body type as well as different 
perceptions of normal body ratio. Specifically, Asian people were found to have increased 
mortality risk at BMI more than 25 in comparison with US population. In addition, Asian 
population tends to have a central obesity which is a major factor for developing 
cardiovascular and metabolic disorders (Lear et al., 2007).  Since BMI has been commonly 
used in studies related to overweight and obesity it was also used in this research.  
 
1.2 TRENDS OF OBESITY IN KAZAKHSTAN 
According to a number of studies Kazakhstan has been showing increasing trend of 
overweight and obesity among adult population. As Helbe and Francisco (2017) showed in 
their research, Kazakhstan among countries of Central Asia like Armenia, Azerbaijan, 
8 
 
Georgia, Kyrgyz Republic, Tajikistan, Turkmenistan and Uzbekistan was the leading in 
absolute numbers of obese people from 1990 to 2013. Specifically, in 2013 Kazakhstan was 
the second obese country among those mentioned. Moreover, change percentage of obesity 
prevalence in Kazakhstan (about 16.6 %) was more than the mean for Central Asia (around 
16.4%) (Helbe and Francisco, 2017). Studies conducted by the Kazakh Academy of Nutrition 
in 2014 revealed that 55.5% of women, 49.2% of men and 14.7% of children suffer from 
overweight or obesity in Kazakhstan (Kazakh Academy of Nutrition, n.d.). 
Data provided by WHO (2017) also demonstrates steady rise of overweight and obesity 
prevalence in Kazakhstan from 1975 to 2016 among adult population. According to WHO 
(2013) in 2020 about 45% of male and 29% of female are expected to be obese. Moreover, by 
2030 the prevalence of obese men will reach 74% and women - 36% (WHO, 2013). These 
predicted estimates highlights the importance of introducing programs to reduce overweight 
and obesity prevalence among Kazakhstan population.      
 
1.3   DISEASES ASSOCIATED WITH OBESITY IN KAZAKHSTAN 
According to Guh et al. (2009) there are 18 co-morbidities associated with overweight and 
obesity including type II diabetes, different types of cancers, CVDs and other such as asthma, 
gallbladder disease, osteoarthritis, chronic back pain. Moreover, as BMI increases the risk of 
getting coronary heart disease, ischemic stroke, type II diabetes and types of cancers 
including breast, colon, prostate and other organs also rises significantly (WHO, 2009). It 
was estimated that 44% of diabetes, 23% of ischemic heart disease and 7–41% of particular 
cancers are attributable to overweight and obesity worldwide (WHO, 2009). Some of these 
disorders have been the leading causes of mortality and morbidity in Kazakhstan.  
It was also reported in Governmental Program for Healthcare Development “Densaulyk” for 
2016-2019 that the leading cause of mortality among Kazakhstan population is 
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cardiovascular diseases accounting for 22.3% of all deaths. The most often met among CVD 
are ischemic heart failure, cerebrovascular injury from which annually dies about 30,000 
people. In addition, there is a positive trend of CVD rise from 2010 to 2014 on almost 15% 
(Governmental Program for Healthcare Development for 2016-2019).  
The second cause of mortality in Kazakhstan is malignant neoplasm accounting for 12.1%. 
Every year there are approximately 17,000 people die from it (Governmental Program for 
Healthcare Development for 2016-2019). It was estimated that approximately 3.6% of cancer 
mortality in adults in 2012 was related to increase BMI. Specifically, in Asian regions the 
population attributable fraction for all cancers ranged from 0.4% to 0.9% in males and from 
1.7% to 3% - females (Arnold et al., 2015).  
In meta-analysis by Guh et al. there were nine studies demonstrating that increased BMI is 
highly associated with type II diabetes in men and women. Since 1995 the rate of type II 
diabetes has been increasing in Kazakhstan. For example, in 1995 there were 35 newly 
diagnosed patients with type II diabetes for 100,000 people, while in 2007 - 116 patients. An 
increase in the number of urban population, increase in the life expectancy of Kazakhstan 
population and increase in the incomes of the population in the next decade will lead to a 
rapid increase in the number of patients suffering from type II diabetes. According to official 
statistics, 5% of the population in country has diabetes. However, screening and analysis of 
ongoing studies show that in fact the number of people with diabetes can reach 5-7%, which 
is consistent with international practice (Tukalevskaya N.N., n.d.). Diabetes requires 
significant amount of money for medical and non-medical care, especially related to its major 
complications including blindness, renal failure, peripheral vascular disease, neuropathy, 
lower limb amputation and CVDS. It was estimated that in 70-80 % of diabetes cases patients 
died because of CVDs caused by diabetes (A.Zh. Ilmalieva et al., 2016).   
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Thus, diseases associated with obesity including CVDs, cancers and diabetes in Kazakhstan 
significantly affect morbidity and mortality rates among population. Moreover, medical care 
of these disorders is mostly covered by government through the special medical services 
package called “Guaranteed package of free medical help”  (Resolution of the Government of 
the Republic of Kazakhstan of January 27, 2014 No. 29). As the prevalence of CVDs, cancers 
and  diabetes is increasing steadily in Kazakhstan there is expected increase of the expenses 
related to them. Since obesity has been found to be one of the major causes for these 
conditions there is a possibility to reduce morbidity by preventing obesity prevalence. In this 
study only three particular diseases has been chosen for the costs estimation which are 
Ischemic Heart Disease, Stroke and Type II Diabetes complications. The main reason is the 
lack of detailed data on prevalence of obesity associated diseases and their costs covered by 
the government.    
 
2. METHODS AND MATERIALS 
2.1 Methods 
The aim of study is to estimate direct medical costs associated with obesity from the 
governmental perspective for 2008, 2020 and 2030. For this purpose, we used cost-of-illness 
approach with governmental perspective to calculate direct medical costs associated with 
obesity based on secondary data. Cost-of-illness approach is used to relate the costs to the 
specific disease and evaluate the expenses that could potentially be saved or gained in case of 
declined rates or eradication of the disease. This approach is commonly used in public health 
policy sphere because it emphasizes the value of the impact of an illness on society and help 
to decide whether it should be addressed by healthcare (Segel, 2006). Cost-of-illness method 
includes prevalence-based and incidence-based approaches (Henriksson et al,. 2000). 
Prevalence-based approach is used to estimate the costs of the illness in one period despite of 
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the date of its onset. This approach also needs less data and fewer assumptions in comparison 
with incidence-based studies. There is only one year related data required ignoring the rates 
of survival and disease course. The main assumption required for this method is that the 
structure of costs and discounting will not change in the future (Segel, 2006). Since this 
approach includes the annual medical costs it is more advantageous method for chronic 
diseases. Therefore, cost-of-illness prevalence-based approach has been chosen for this 
particular study (Henriksson et al,. 2000).    
 
2.2 Data sources 
There are three types of data required to use in the estimations for this study. The first type of 
data is actual and predicted obesity prevalence for 2008, 2020 and 2030 which was taken 
from the WHO (2013) (see Table 1). Relative risks for the obesity attributable diseases to 
calculate PAF were taken from the World obesity official website (World Obesity, 2015) (see 
Table 2). Since required data of the direct medical costs related to IHD, stroke and T2D 
complications from the governmental perspective are not available in public registers costs 
estimates were taken from the secondary data (A.Zh. Ilmalieva et al., 2016) (see Table 3). 
Thus, these calculations reflect costs that really affect the health care system in the form of 
costs for hospitalization, concomitant pharmacotherapy and the provision of medical services 
(A.Zh. Ilmalieva et al., 2016). 
The costs of specific diseases attributable to obesity were derived by multiplying the PAFs 
(Population Attributable Fractions) for disease prevalence (see Table 4) and medical costs 
(Botticello et al., 2015). 
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2.3 ESTIMATING THE DIRECT COSTS OF OBESITY 
2.3.1 Calculating PAFs for T2D, IHD and stroke  
Formula used to calculate Population Attributable Fraction (PAF) (Botticello et al., 2015): 
 
P(E)*(RR-1)/((P(E)*(RR-1))+1 
 
where P(E)is defined as a proportion of the obesity exposed population; RR stands for 
relative risk for specific diseases associated with obesity (Botticello et al., 2015).  
Note: all the necessary calculations for this study are shown in the 7. Table and Figures and 
called “Calculation part”. 
 
2.3.2 Calculating medical direct costs for T2D, IHD and stroke  
 
Medical direct costs were estimated using the following formula (Botticello et al., 2015): 
 
 
PAF of disease * Costs for disease treatment per one patient* Disease prevalence 
 
 
PAF of diseases is calculated according to the previously mentioned formula. Costs for 
disease treatment per one patient are taken from the secondary data by A.Zh. Ilmalieva et al. 
(2016) (see Table 2). It should be mentioned that available costs were only for 2013, so these 
costs were used in calculations for 2008, 2020 and 2030. Also the conversion from KZT to 
USD was according to 2013 currency rates. Disease prevalence is the prevalence of particular 
disease taken from the secondary data (see Table 3). The main assumption that should be 
taken into account is that the relative risks, costs for the treatment and obesity associated 
disease prevalence taken from the secondary data were the same through the calculation 
process. It means that the only changing variable in the formula was Population Attributable 
Fraction due to increasing obesity prevalence actual and predicted estimates for 2008,  2020 
and 2030.    
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Note: all the necessary calculations for this study are shown in the 7. Table and Figures 
from Table 5 to Table 10.  
 
3. RESULTS 
The results of PAF estimation showed the overall increasing trend through 2008, 2020 and 
2030 years for every disease. Since PAF depends directly on obesity prevalence it is 
expected that overall PAF trend would be positive as obesity prevalence is predicted to 
increase over years. According to Figure 1, in general, the biggest PAFs were related to 
T2D. It is explained by the highest relative risk of getting T2D due to obesity which is 5.5 
for men and 7.0 for women. Relative risks for IHD and stroke are considerable lower 
indicating 2.0 for both sexes and 1.5 for men and 1.55 for woman, respectively. So, PAFs 
related to IHD for 2008, 2020 and 2030 were 0.19, 0.2675 and 0.345, respectively; stroke 
PAFs were 0.1095, 0 .161 and 0.2175 for 2008, 2020 and 2030, respectively; T2D 
accounted for 0.5425, 0.651 and 0.725 (see Table 11).  
Figure 1. Results of the calculations of PAFs for 2008, 2020 and 2030 years 
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According to Figure 2, medical direct costs estimation also showed the overall increasing 
trend through 2008, 2020 and 2030 years for every disease. Since PAF showed increasing 
rate through the provided years it is expected to see increasing rate of the costs. In general, 
the biggest PAFs were related to T2D which is also explained by highest relative risk for 
T2D attributable to obesity. So, direct costs related to IHD for 2008, 2020 and 2030 were 
4,105,120.939 USD, 5,778,447.353 USD and 7,452,576.96 USD, respectively; stroke 
costs were 2,152,615.478 USD, 3,165,032.803 USD and 4,275,743.073 USD for 2008, 
2020 and 2030; T2D accounted for 60,415,137.31 USD, 72,665,211.23 USD and 
80,739,123.58 USD (see Table 12).  
Figure 2. Estimated medical direct costs related to IHD, stroke and T2D diabetes for 
2008, 2020 and 2030 
 
4. DISCUSSION 
It was reported by WHO (2009) that non-communicable chronic diseases will become the 
major cause for morbidity and mortality in the nearest future. It was estimated that by 2020 
about two-thirds of all disease would be non-communicable chronic diseases. In connection 
with the practical widespread increase in the frequency of obesity, WHO describes it as an 
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epidemic disease that has tangible economic consequences. In developed countries, the total 
cost of treating obese patients and their consequences is about 10% of total health care 
expenditure, and the direct costs of 3% to 5% of total expenditure (Kazakh Academy of 
nutrition, n.d.). It was also estimated that obese individuals tend to spend 30% greater on 
their medical services than those, with normal weight (Withrow, D., & Alter, D. A., 2011).  
Results of this study showed that the estimated costs for IHD and stroke would increase twice 
by 2030 and increase by ⅓ for T2D complications. Combined direct medical costs for these 
three disorders accounts for 100 million USD and the actual future costs most probably will 
increase significantly due to currency changes, medical service and drug costs increase and 
country’s economic status.  
There is a free medical help for the population which is provided by the government of 
Kazakhstan through the special medical services package called “Guaranteed package of free 
medical help” (hereafter - GPoFMH). GPoFMH is granted to citizens of the Republic of 
Kazakhstan and oralmans at the expense of budgetary funds and includes preventive, 
diagnostic and therapeutic medical services with the highest proven effectiveness. It includes 
1) ambulance; 2) out-patient care, including primary health care; 3) inpatient medical care; 4) 
rehabilitation; 5) palliative care and nursing care for the categories of the population 
established by the Government of the Republic of Kazakhstan (Resolution of the Government 
of the Republic of Kazakhstan of January 27, 2014 No. 29). 
According to the Governmental Program for Healthcare Development “Densaulyk” for 2016-
2019 there is 1,969,729, 500 KZT dedicated for this program. From this budget 128,034,799 
KZT is dedicated for 2016; 408,080,865 KZT - for 2017; 709,797,105 KZT - for 2018 and 
723,816,732 KZT for 2019. So, according to the obtained results, costs associated with IHD, 
stroke and T2D attributable to obesity in Kazakhstan by 2020 will reach 81,608,691 KZT 
accounting for 11.3% from the money dedicated for 2019 of the Governmental Program for 
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Healthcare Development “Densaulyk” for 2016-2019. That is considerable proportion of 
share for only three diseases taking into account that the estimated costs most probably is the 
minimum expenses country is going to be spent in the future. These estimations demonstrate 
the value of introducing effective interventions against obesity. 
Taking into account that in 98% of cases obesity develops when the energy intake exceeds 
its consumption, and for a long time, as well as the above changes in the structure of 
nutrition, it should be stressed about the enormous importance of explanatory work and 
the promotion of a healthy lifestyle to help people to change the behavior pattern in order 
to prevent not only overweight and obesity, but also other non-infectious diseases (Center 
of Healthy Lifestyle Development of Astana, n.d.). If the appropriate effective measures 
are not taken immediately, the costs related to obesity might become catastrophic not only 
due to significant rise in medical service costs but also from declined worker productivity 
including  physical and psychological disabilities (Hojjat T. A., 2015).   
There are expected indicators of obesity for 2016-2019 reported in Governmental Program of 
Healthcare Development “Densaulyk”. So, the actual estimates for 2014 were 278,3 obese 
people per 100,000 and the expected reduction is to 256,5 people per 100,000 in 2016, 243,6 
- in 2017, 231,4 - 2018 and 220,0 - in 2019 (Governmental Program for Healthcare 
Development, 2016-2019).  Although the reduction rate is gradual there is no described clear 
strategy to reach these indicators. Nevertheless, there are newly established Public Health 
Services and already functioning Centers for Healthy Lifestyle Development and National 
Center for problems of healthy lifestyle formation one of the functions is to target the issue of 
healthy lifestyle in Kazakhstan population including obesity prevalence reduction 
(Governmental Program for Healthcare Development, 2016-2019). However, there is not 
enough information on the official sites of these centers on the programs to tackle the 
problem of adult obesity in Kazakhstan or particular cities and regions of Kazakhstan.   
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There are general recommendations on tackling obesity worldwide provided by WHO in 
Global Strategy on Diet, Physical Activity and Health: 
• Public and private sector, including all individuals and organizations engaged in the 
production, promotion and sale of food, should review their policies (both on a voluntary 
basis and on the basis of appropriate legislation) that should be oriented towards the 
prevention of obesity; 
• Professional organizations should support measures aimed at the prevention and treatment 
of obesity and related diseases; 
• Consumer organizations should join forces in order to better inform the public about 
obesity; 
• Intergovernmental organizations should endeavor to ensure that concerted action is taken at 
the international level, and for this purpose they should develop and adopt appropriate 
guidelines and policy recommendations (Kazakh Academy of Nutrition, n.d.).  
There are also some approaches to solve the issue of obesity prevalence described by Hojjat, 
T. A. (2015). The first one is food policy interventions at the national and international level 
to make healthy food available financially and geographically. WHO reported that the one of 
the approaches to maintain normal weight is to consume fresh nutrient-rich foods. One of the 
approaches to reach this target is to reduce the demand for products and to change the 
lifestyle that contributes to obesity by educating population, taxing products and food 
labeling (Hojjat, T. A., 2015). The second way is to decline the provision side by cutting 
subsidies of agricultural products so the costs still are low. So, imposing taxes on fats and 
sweets at schools could lead to limited access to vending machines containing beverages and 
snacks (Hojjat, T. A., 2015). For example, recently in Kazakhstan universities and schools 
banned the sale of sweet fizzy and energy drinks (tengrinews.kz). Another approach is to 
provide incentives for the agricultural sector to produce healthier goods. For example, it was 
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calculated that 73 percent of corn-derived sweeteners per person per year is consumed in 
USA. The main reason is subsidizing corn-derived production by the government resulting in 
production of unhealthy sweeteners instead of contributing to the healthier natural sweeteners 
Hojjat, T. A. (2015).  
Some studies provide unordinary approach to reduce adult obesity. It was suggested and 
supported by evidence that walking and playing with dogs could change sedentary 
lifestyle and promote healthy lifestyle resulting in obesity reduction.  It was recommended 
to investigate this approach to address the issue of obesity (Boisvert, J. A., & Harrell, W. 
A., 2014). 
Thus, there are several ways to target adult obesity, globally, and the government should 
take this issue under control to prevent future negative consequences both, public health 
and financial.   
 
4.2 STRENGTHS AND LIMITATIONS 
There are several strengths and limitations for this study. Although there is extensive 
knowledge regarding prevalence, determinants and consequences of obesity there is no 
official published articles related to this topic in Kazakhstan. So, this research reveals first 
estimates of the costs associated with obesity in Kazakhstan and provide valuable information 
for the further possible cost-effectiveness and cost-benefit analyses (Segel, 2006). The second 
strength is that the results of this research might be used to estimate the risks of the obesity 
prevalence in Kazakhstan and grab government’s attention to the adult overweight and 
obesity and financial consequences related to this issue. 
One of the limitations to be mentioned is the lack of detailed costs for the outpatient and 
inpatient services, drug costs, rehabilitation, nursing care and other expenses per patient in 
Kazakhstan. If necessary data on costing would be provided the range of included diseases in 
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this study could be extended including different cancer types, CVDs and other obesity-
associated disorders. To obtain more accurate results D.Razzouk (2017) recommends to 
collect individual data through a micro-costing bottom-up method.  
 
4.3 FURTHER RECOMMENDATIONS 
One of the further research recommendations related to this topic would be including more 
diseases in the analysis to cover extended range of consequences attributable to overweight 
and obesity. Moreover, in-direct medical costs are also considerable part of the expenses 
taken by population, so it is important to conduct researches including in-direct costs 
associated with obesity.  
From the practical perspective it would be beneficial to use the results to inform the 
government and population about significant expenses related to the obesity so the necessary 
actions would be taken to prevent future negative consequences.     
 
5. CONCLUSION 
According to the results of this study the direct medical costs covered by government in 
Kazakhstan are going to increase twice for IHD and stroke and by ⅓ for T2D complications 
by 2030. Taking into account that no adjustments were used for the future currency changes, 
medical services and drug costs the future direct medical costs might be significantly higher 
than it was estimated in the study. Specifically, interventions targeting adults who are already 
overweight and obese are as important as obesity prevention programs targeting children and 
teenagers. The main purpose of this research was to inform, using economic rationale, the 
governmental planning of obesity control initiatives. It should be mentioned that significant 
amount of money might be saved in the future if required actions are taken by the 
government.     
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Tables and Figures 
Table 1. Obesity prevalence for 2008, 2020 and 2030 in Kazakhstan 
 2008  
(actual estimates) 
2020 
 (predicted 
estimates) 
2030 
 (predicted 
estimates) 
Male 19.1% 
 
45% 74% 
 
Female 27.6% 29% 
 
36% 
 
Reference: WHO, 2013 
 
Table 2. Estimated relative risk of diseases attributable to obesity 
 
Disease RR Obesity 
(men) 
RR Obesity 
(women) 
IHD 2.00 2.00 
Stroke 1.50 1.55 
T2D 5.50 7.00 
Reference: World obesity, 2015 
 
 
Table 3. Medical costs covered by government per patient  
 
Disease  Costs for one treated case established by 
order of Ministry of healthcare for 2013 
(KZT) 
Stroke 62,051 
Myocardial infarction 183,411 
Blindness 36,300 
IHD 67,503.3 
Heart failure 71,743 
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Stenocardia 106,509 
Amputation 41,499 
Microvascular complications 61,423 
Cataract 57,238 
Reference: A.Zh. Ilmalieva, G.K. Moldabek, Zh.A. Akanov, 2016.  
Table 4. Prevalence of IHD, stroke and T2D in Kazakhstan in 2008  
Disease Prevalence for 2008 
IHD 49,067 cases 
Stroke  48,577 cases 
 
T2D 144,440 cases 
 
References: Data for IHD is retrieved from 
https://online.zakon.kz/Document/?doc_id=37488639#pos=1;-161 - Statistics of the 
incidence and prevalence of socially significant diseases in Kazakhstan., n.d. 
Data for stroke is retrieved from Morozova T.M., 2016 
Data for diabetes is retrieved from 
https://online.zakon.kz/Document/?doc_id=37488639#pos=1;-161 - Statistics of the 
incidence and prevalence of socially significant diseases in Kazakhstan., n.d. 
Calculation part 
 
Calculations of PAFs for 2008 year 
 
IHD (men) = 0.191*(2-1)/0.191*(2-1)+1 = 0.16 
IHD (women) = 0.276*(2-1)/0.276*(2-1)+1 = 0.22 
IHD (average) = (0.16+0.22)/2 = 0.19 
 
Stroke (men) = 0.191*(1.5-1)/0.191*(1.5-1)+1 = 0.087 
Stroke (women) = 0.276*(1.55-1)/0.276*(1.55-1)+1 = 0.132 
Stroke(average) = (0.087+0.132)/2 = 0.1095 
 
T2D (men) = 0.191*(5.5-1)/0.191*(5.5-1)+1 = 0.462 
T2D (women) = 0.276*(7.0-1)/0.276*(7.0-1)+1 = 0.623 
26 
 
T2D (average) = (0.462+0.623)/2 = 0.5425 
 
Calculations of PAFs for 2020 year 
 
IHD (men) = 0.45*(2-1)/0.45*(2-1)+1 = 0.31 
IHD (women) = 0.29*(2-1)/0.29*(2-1)+1 = 0.225 
IHD (average) = (0.31+0.225)/2 = 0.2675 
 
Stroke (men) = 0.45*(1.5-1)/0.45*(1.5-1)+1 = 0.184 
Stroke (women) = 0.29*(1.55-1)/0.29*(1.55-1)+1 = 0.138 
Stroke (average) = (0.184+0.138)/2 = 0.161 
 
T2D (men) = 0.45*(5.5-1)/0.45*(5.5-1)+1 = 0.67 
T2D (women) = 0.29*(7.0-1)/0.29*(7.0-1)+1 = 0.635 
T2D  (average) = (0.67+0.635)/2 = 0.6525 
 
Calculations of PAFs for 2030 year 
 
IHD (men) = 0.74*(2-1)/0.74*(2-1)+1 = 0.425 
IHD (women) = 0.36*(2-1)/0.36*(2-1)+1 = 0.265 
IHD (average) = (0.425+0.265)/2 = 0.345 
 
Stroke (men) = 0.74*(1.5-1)/0.74*(1.5-1)+1 = 0.27 
Stroke (women) = 0.36*(1.55-1)/0.36*(1.55-1)+1 = 0.165 
Stroke (average) = (0.27+0.165)/2 = 0.2175 
 
T2D (men) = 0.74*(5.5-1)/0.74*(5.5-1)+1 = 0.77 
T2D (women) = 0.36*(7.0-1)/0.36*(7.0-1)+1 = 0.68 
T2D  (average) = (0.77+0.68)/2 = 0.725 
 
Table 5. Calculations of costs for IHD and stroke for 2008 year 
 
Disease Calculations of the 
costs (PAF*Costs 
per patient) 
Results per 
one patient 
Calculations for all 
cases (results per 
one patient*disease 
prevalence) 
Total results 
(KZT) 
Total results 
(USD) 
IHD  0.19*67 503.3 12,825.627 12,825.627*49,067 629,315,040 4,105,120.939 
Stroke  0.1095*62,051 6,794.5845 6,794.5845*48,577 330,060,531.3 2,152,615.478 
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Table 6. Calculations of costs for IHD and stroke for 2020 year 
 
Disease Calculations of 
the costs 
(PAF*Costs per 
patient) 
Results per 
one patient 
Calculations for all 
cases (results per 
one patient*disease 
prevalence) 
Total results 
(KZT) 
Total results 
(USD) 
IHD  0.2675*67,503.3 18,057.13275 
 
18,057.13275*49,067 88,600,9332.6 5,778,447.353 
Stroke  0.161*62,051 9,990.211 9,990.211*48,577 485,294,479.7 3,165,032,803 
 
Table 7. Calculations of costs for IHD and stroke for 2030 year 
 
Disease Calculations 
of the costs 
(PAF*Costs 
per patient) 
Results per 
one patient 
Calculations for all 
cases (results per 
one patient*disease 
prevalence) 
Total results 
(KZT) 
Total results 
(USD) 
IHD  0.345*67,503.3 23,288.6385 23,288.6385*49,067 
 
1,142,703,625 7,452,576.96 
Stroke  0.2175*62,051 13,496.0925 13,496.0925*48,577 655,599,685.4 4,275,743.073 
 
Table 8. Calculations of costs for T2D complications for 2008 year 
T2D 
complication 
type 
Calculations of 
the costs 
(PAF*Costs per 
patient) 
Results per 
one patient 
Calculations for all 
cases (results per 
patient*coefficient(
*)*disease 
prevalence) 
Total results 
(KZT) 
Total results 
(USD) 
CVD  0.5425*55,2640.3 299,807.3628 299,807.3628 
*0.1605*144,440 
 
6,950,320,165 45,329,160.41 
Retinopathy  0.5425*93,538 50,744.365 50,744.365 
*0.3045*144,440 
2,231,837,646  
14,555,779.34 
Amputation 0.5425*41,499 
 
22,513.2075 22,513.2075*0.025 
*144,440 
 
81,295,192.28 530,197.5627 
TOTAL 60,415,137.31 
Note: CVD includes stroke, myocardial infarction,IHD,heart failure,  stenocardia, microvascular complications; 
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retinopathy includes blindness and cataracts 
Coefficient stands for the risk of getting particular complication due to T2D and retrieved from Gan, D. (2003). 
 
Table 9. Calculations of costs for T2D complications for 2020 year 
T2D 
complication 
type 
Calculations of 
the costs 
(PAF*Costs per 
patient) 
Results per 
one patient 
Calculations for 
all cases (results 
per patient* 
coefficient(*) 
*disease 
prevalence) 
Total results 
(KZT) 
Total results 
(USD) 
CVD  0.6525*552,640.3 360,597.7958 360,597.7958 
*0.1605*144,440 
 
8,359,601,673 54,520,326.57 
Retinopathy  0.6525*93,538 
 
61,033.545 61,033.545 
*0.3045*144,440 
 
2,684,376,155 17,507,181.6 
Amputation 0.6525*41,499 27,078.0975 27,078.0975 
*0.025*144,440 
 
97,779,010.07 637,703.0592 
TOTAL 72,665,211.23 
Note: CVD includes stroke, myocardial infarction,IHD,heart failure,  stenocardia, microvascular complications; 
retinopathy includes blindness and cataracts 
Coefficient stands for the risk of getting particular complication due to T2D and retrieved from Gan, D. (2003). 
 
Table 10. Calculations of costs for T2D complications for 2030 year 
T2D 
complication 
type 
Calculations of 
the costs 
(PAF*Costs per 
patient) 
Results per 
one patient 
Calculations for 
all cases (results 
per patient* 
coefficient(*) 
*disease 
prevalence) 
Total results 
(KZT) 
Total results 
(USD) 
CVD  0.725*552,640.3 400,664.2175 400,664.2175 
*0.1605*144,440 
9,288,446,302 60,578,140.62 
Retinopathy  0.725*93,538 67,815.05 67,815.05 
*0.3045*144,440 
2,982,640,173 19,452,424.01 
Amputation 0.725*41,499 
 
30,086.775 30,086.775 
*0.025*144,440 
108,643,344.5 708,558.9547 
TOTAL 80,739,123.58 
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Note: CVD includes stroke, myocardial infarction,IHD,heart failure,  stenocardia, microvascular complications; 
retinopathy includes blindness and cataracts 
Coefficient stands for the risk of getting particular complication due to T2D and retrieved from Gan, D. (2003). 
 
Table 11. Results of the calculations of PAFs for 2008,2020 and 2030 years 
 
Disease PAFs for 2008  PAFs for 2020 PAFs for 2030 
IHD   0.19 0.2675 0.345 
Stroke   0.1095 0 .161 0.2175 
T2D   0.5425 0.651 0.725 
 
Table 12. Estimated medical direct costs related to IHD, stroke and T2D diabetes for 
2008, 2020 and 2030 
Disease Costs for 2008 
(USD) 
Costs for 2020 
(USD) 
Costs for 2030 
(USD) 
IHD  4,105,120.939 5,778,447.353 7,452,576.96 
Stroke  2,152,615.478 3,165,032.803 4,275,743.073 
T2D complications 60,415,137.31 72,665,211.23 80,739,123.58 
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